ENGN · enGene Therapeutics Inc. · Supply Chain
$1.58
-0.09 (-5.39%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— cleared Jun 15, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities as of April 30, 2026 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.”View the 10-Q filed Jun 15, 2026
Market Cap
$105.89M
Shares
67.02M
Volume · Oct 19
783.85K
Avg daily vol (3M)
735.99K
Supply Chain
Customers, suppliers, competitors and partners named in annual 10-K reports: ENGN's own, and those of other companies that name ENGN.
Read supply chains in your AI or your code through MCP and the API →
Pro
See who ENGN sells to, buys from and competes with
- 0 suppliers
- 0 customers
- 14 competitors
Pro names each company, links it to its own page, shows any revenue share the filing states, and quotes the sentence it comes from.